[1] Ho L T, Sprague S M.Women and CKD-mineral and boen disorder[J]. Adv Chronic Kidney Dis, 2013, 20(5):423-426.
[2] Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO)[J]. Kidney Int, 2006, 69(11): 1945-1953.
[3] Coen G, Ballanti P, Bonucci E, et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients[J]. Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Ren Assoc, 1998, 13(9): 2294-2302.
[4] Ott S M.Histomorphometric measurements of bone turnover, mineralization, and volume[J]. Clin J Am Soc Nephrol, 2008, 3(Suppl 3): S151-S156.
[5] Koos R, Brandenburg V, Mahnken A H, et al. Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study[J]. J Heart Valve Dis, 2013, 22(3): 317-325.
[6] Delanaye P, Souberbielle J C, Lafage-Proust M H, et al. Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts[J]. Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Ren Assoc 2014, 29(5): 997-1004.
[7] Delanaye P, Dubois B E, Jouret F, et al. Parathormone and bone-specific alkaline phosphatase for the follow-up of bone turnover in hemodialysis patients: is it so simple[J]? Clin Chim Acta, 2013, 417: 35-38.
[8] Evenepoel P, Bover J, Urena Torres P.Parathyroid hormone metabolism and signaling in health and chronic kidney disease[J]. Kidney Int, 2016, 90(6): 1184-1190.
[9] Christiansen P, Steiniche T, Vesterby A, et al. Primary hyperparathyroidism: iliac crest trabecular bone volume, structure, remodeling, and balance evaluated by histomorphometric methods[J]. Bone , 1992, 13(1): 41-49.
[10] Rosso R, Minisola S, Scarda A, et al. Temporal relationship between bone loss and increased bone turnover: a longitudinal study following natural menopause[J]. J Endocrinol Invest, 1995, 18(9): 723-728.
[11] D’Haens G, Verstraete A, Cheyns K, et al. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn’s disease[J]. Aliment Pharmacol Ther, 1998, 12(5): 419-424.
[12] Behets G J, Spasovski G, Sterling L R, et al. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism[J]. Kidney Int, 2015, 87(4): 846-856.
[13] Steiniche T, Christiansen P, Vesterby A, et al. Primary hyperparathyroidism: bone structure, balance, and remodeling before and 3 years after surgical treatment[J]. Bone, 2000, 26(5): 535-543.
[14] Sprague S M, Bellorin-Font E, Jorgetti V, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis[J]. Am J Kidney Dis, 2016, 67(4):559-566.
[15] Rahman M S, Akhtar N, Jamil H M, et al. TGF-beta/BMP signaling and other molecular events:regulation of osteoblastogenesis and bone formation[J]. Bone Res, 2015, 3(1): 11-30.
[16] Ardawi M S, Rouzi A A, Qari M H.Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study[J]. J Clin Endocrinol Metab, 2012, 97(10): 3691-3699.
[17] Kidney Disease: Improving Global Outcomes CKDMBDWG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention,treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)[J]. Kidney Int, 2009, Supplement(113): S1-S130.
[18] Fernandez-Martin J L, Martinez-Camblor P, Dionisi M P, et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study[J]. Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Ren Assoc, 2015, 30(9): 1542-1551.
[19] Torres A, Lorenzo V, Hernandez D, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH[J]. Kidney Int, 1995, 47(5): 1434-1442.
[20] Wang M, Hercz G, Sherrard D J, et al. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity[J]. Am J Kidney Dis, 1995, 26(5): 836-844.
[21] Magnusson P, Sharp C A, Magnusson M, et al. Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms[J]. Kidney Int, 2001, 60(1):257-265.
[22] Johnson K A, Hessle L, Vaingankar S, et al. Osteoblast tissue-nonspecific alkaline phosphatase antagonizes and regulates PC-1[J]. Am J Physiol Regul Integr Comp Physiol, 2000, 279(4): R1365-R1377.
[23] Haarhaus M, Monier-Faugere M C, Magnusson P, et al. Bone alkaline phosphatase isoforms in hemodialysis patients with low versus non-low bone turnover: a diagnostic test study[J]. Am J Kidney Dis, 2015, 66(1): 99-105.
[24] Drechsler C, Verduijn M, Pilz S, et al. Bone alkaline phosphatase and mortality in dialysis patients[J]. Clin J Am Soc Nephrol, 2011, 6(7): 1752-1759.
[25] Robinson-Cohen C, Katz R, Hoofnagle A N, et al. Mineral metabolism markers and the long-term risk of hip fracture: the cardiovascular health study[J]. J Clin Endocrinol Metab, 2011, 96(7): 2186-2193.
[26] Urena P, Hruby M, Ferreira A, et al. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients[J]. J Am Soc Nephrol, 1996, 7(3): 506-512.
[27] Wheater G, Elshahaly M, Tuck S P, et al. The clinical utility of bone marker measurements in osteoporosis[J]. J Transl Med, 2013, 11(1): 201.
[28] Zimmermann E A, Busse B, Ritchie R O.The fracture mechanics of human bone: influence of disease and treatment[J].Bonekey Rep, 2015, 4: 743.
[29] Vasikaran S D, Chubb S P, Ebeling P R, et al. Harmonised Australian reference intervals for serum PINP and CTX in adults[J]. Clin Biochem Rev 2014, 35(4): 237-242.
[30] Baim S, Miller P D.Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw[J]. J Bone Miner Res, 2009, 24(4): 561-574.
[31] Pascale Chavassienx.Are biochemical markers of bone turnover representative of bone histomorphonmetry in 370 postmenopausal women[J]. J Clin Endocrimol Metab, 2015, 100(12): 4662-4668.
[32] Seibel M J.Biochemical markers of bone turnover: part I: biochemistry and variability[J]. Clin Biochem Rev, 2005, 26(4): 97-122.
[33] Lv Y, Wang G, Xu W, et al. Tartrateresistant acid phosphatase 5b is a marker of osteoclast number and volume in RAW 264.7 cells treated with receptor-activated nuclear kappaB ligand[J]. Exp Ther Med, 2015, 9(1): 143-146.
[34] Yamada S, Inaba M, Kurajoh M, et al. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction[J]. Clin Endocrinol (Oxf), 2008, 69(2): 189-196.
[35] Shidara K, Inaba M, Okuno S, et al. Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients[J]. Calcif Tissue Int, 2008, 82(4): 278-287.